Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda
- Status
- TERMINATED
- Phase
- PHASE1
Clinical Trials Related to Rituximab
Related studies linked through entity extraction aliases.
Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation
- Status
- TERMINATED
- Phase
- PHASE2
Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis
- Status
- RECRUITING
- Phase
- PHASE2
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE2
Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age
- Status
- COMPLETED
- Phase
- PHASE2
Autologous Transplant To End NMO Spectrum Disorder
- Status
- WITHDRAWN
- Phase
- PHASE2/PHASE3
Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide
- Status
- TERMINATED
- Phase
- PHASE2
Personalized Medicine for Membranous Nephropathy
- Status
- COMPLETED
- Phase
- PHASE2
Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL
- Status
- UNKNOWN
- Phase
- PHASE1
Multicenter Registry of Pediatric Lupus Nephritis in China
- Status
- UNKNOWN
- Phase
- N/A
Clinical and Immunological Long-term Follow-up of Patients With Pemphigus Included in the "RITUXIMAB 3" Trial
- Status
- COMPLETED
- Phase
- PHASE3
Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers
- Status
- TERMINATED
- Phase
- PHASE1
MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)
- Status
- UNKNOWN
- Phase
- PHASE3
PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant
- Status
- COMPLETED
- Phase
- EARLY_PHASE1